1 2 3 4
News & Information
A Small Number Of Men With Prostate Cancer Are Super Responders to Immunotheraphy A Small Number Of Men With Prostate Cancer Are Super Responders to Immunotheraphy
Results from a new clinical trial have shown that some men with advanced prostate cancer can live for at least two more years on immunotherapy after exhausting all other treatment options...
Psychosocial Concerns Common After Prostate Cancer Treatment Psychosocial Concerns Common After Prostate Cancer Treatment
Psychosocial problems that adversely affect quality of life are common among men after receiving treatment for prostate cancer, and they need help....
Enrollment Completed for Phase 3 Trial Testing Provenge in Prostate Cancer Patients on Active Surveillance Enrollment Completed for Phase 3 Trial Testing Provenge in Prostate Cancer Patients on Active Surveillance
Dendreon Pharmaceuticals has completed patient enrollment ahead of schedule in an ongoing Phase 3 trial
Men Over 40 With BRCA2 Mutations Must Get Prostate Cancer Screening, Experts Say Men Over 40 With BRCA2 Mutations Must Get Prostate Cancer Screening, Experts Say
Researchers have called for immediate action to recommend screening for prostate cancer for men with BRCA2 mutations over the age of 40. 
Increasing Diversity in Clinical Trials

Clinical trials lead to the approval of new drugs.  A recent article reported that black enrollment is extremely low; limiting our understanding of how these drugs effect blacks...
One Two Punch could slow the spread of cancer

There is no one pathway, which controls prostate cancer growth, more clinical trials are being designed using more than one drug. This ONE TWO punch design could slow the spread of cancer. 
Partners